XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.23.2

REVENUE (Tables) | 9 Months Ended
--- | ---
Jul. 31, 2023
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended July 31,
| 2023 |  | 2022
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 312 |  |  | $ | 159 |  |  | $ | 196 |  |  | $ | 667 |  |  | $ | 336 |  |  | $ | 147 |  |  | $ | 188 |  |  | $ | 671 |
Europe | 217 |  |  | 108 |  |  | 107 |  |  | 432 |  |  | 210 |  |  | 94 |  |  | 103 |  |  | 407 |
Asia Pacific | 398 |  |  | 129 |  |  | 46 |  |  | 573 |  |  | 473 |  |  | 118 |  |  | 49 |  |  | 640 |
Total | $ | 927 |  |  | $ | 396 |  |  | $ | 349 |  |  | $ | 1,672 |  |  | $ | 1,019 |  |  | $ | 359 |  |  | $ | 340 |  |  | $ | 1,718 |
| Nine Months Ended July 31,
| 2023 |  | 2022
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 954 |  |  | $ | 467 |  |  | $ | 609 |  |  | $ | 2,030 |  |  | $ | 974 |  |  | $ | 416 |  |  | $ | 577 |  |  | $ | 1,967 |
Europe | 701 |  |  | 309 |  |  | 311 |  |  | 1,321 |  |  | 678 |  |  | 289 |  |  | 314 |  |  | 1,281 |
Asia Pacific | 1,273 |  |  | 388 |  |  | 133 |  |  | 1,794 |  |  | 1,239 |  |  | 366 |  |  | 146 |  |  | 1,751 |
Total | $ | 2,928 |  |  | $ | 1,164 |  |  | $ | 1,053 |  |  | $ | 5,145 |  |  | $ | 2,891 |  |  | $ | 1,071 |  |  | $ | 1,037 |  |  | $ | 4,999 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Nine Months Ended
| July 31, |  | July 31,
| 2023 |  | 2022 |  | 2023 |  | 2022
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 592 |  |  | $ | 643 |  |  | $ | 1,843 |  |  | $ | 1,834 |
Chemicals and Advanced Materials | 378 |  |  | 389 |  |  | 1,162 |  |  | 1,097 |
Diagnostics and Clinical | 241 |  |  | 234 |  |  | 730 |  |  | 718 |
Food | 151 |  |  | 151 |  |  | 472 |  |  | 446 |
Academia and Government | 146 |  |  | 139 |  |  | 451 |  |  | 426 |
Environmental and Forensics | 164 |  |  | 162 |  |  | 487 |  |  | 478 |
Total | $ | 1,672 |  |  | $ | 1,718 |  |  | $ | 5,145 |  |  | $ | 4,999 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 643 |  |  | $ | 737 |  |  | $ | 2,091 |  |  | $ | 2,074 |
Non-instrumentation and other | 1,029 |  |  | 981 |  |  | 3,054 |  |  | 2,925 |
Total | $ | 1,672 |  |  | $ | 1,718 |  |  | $ | 5,145 |  |  | $ | 4,999 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2023:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2022 |  | $ | 557 |
Net revenue deferred in the period |  | 438 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (368) |
Change in deferrals from customer cash advances, net of revenue recognized |  | (24) |
Currency translation and other adjustments |  | 19 |
Ending balance as of July 31, 2023 |  | $ | 622 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration